Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California's TorreyPines Therapeutics has signed its second major Alzheimer's disease drug discovery alliance with Japan's Eisai Co, a global leader in Alzheimer's research and treatment.
Subscribe to our email newsletter
The goal of the research performed by TorreyPines Therapeutics will be to discover novel Alzheimer’s disease modifying agents based on the study of the mechanism of the disease’s pathogenesis.
Under the agreement, Eisai will have exclusive rights of first negotiation and refusal for validated compounds discovered through the research. Eisai and TorreyPines Therapeutics may also enter into drug development agreements involving certain validated compounds that meet pre-determined criteria.
“We are pleased to work with Eisai once again in the field of Alzheimer’s disease therapeutics,” said Dr Neil Kurtz, president and CEO of TorreyPines Therapeutics. “We look forward to advancing this program with Eisai’s support, as well as continuing to work with them on our first research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer’s disease.”
TorreyPines Therapeutics and Eisai entered into their first discovery alliance agreement in Alzheimer’s disease in March 2001.